Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint
– Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protection
– BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 billion per year1 addressable market and projected annual peak sales of $2752 million in the U.S.
– Expected to be earnings accretive by 2024
WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced it has completed the acquisition of the entire …
Read the source article at Financial Research & Reports Finder